SimpliciTB Trial Results Presented at CROI 2023
SEATTLE (February 20, 2023)—Results of TB Alliance’s SimpliciTB clinical trial were presented today at the 30th annual CROI 2023 conference.
Press Releases
Qurient Co. Ltd. and TB Alliance Announce Exclusive License Agreement for Telacebec (Q203), a New Anti-Tuberculosis Agent
SEONGNAM-SI, South Korea and NEW YORK, US. Qurient Co. Ltd. (“Qurient”, KRX: 115180), a clinical-stage biotechnology company based in South
Innovation Deficit: Funds for Neglected Diseases like TB are Falling Short
NEW YORK (January 31, 2023)—The 2022 G-FINDER Report, released today, reveals that for the year 2021, global funding for the
8 Things to Know about Drug-Resistant Tuberculosis
By: Sandeep Juneja, Senior Vice President, Market Access Drug-resistant tuberculosis (DR-TB) forms when long, complex, outdated drug regimens are improperly
Price reduction paves the way for expanded access to highly effective multidrug-resistant tuberculosis treatment
19 December 2022: Viatris, a global healthcare company, MedAccess, and TB Alliance have announced a new agreement to reduce the
New Study: Recently Approved Drug-Resistant TB Treatments Can Save National Governments up to US$740 Million Annually
PRETORIA (16 November, 2022)—A new study published in PLOS Global Public Health found that the BPaLM/BPaL treatment regimen that will
WHO’s new TB numbers highlight an emergency in need of action
“The tuberculosis situation is urgent. TB is again the biggest single killer globally of any infectious disease, including COVID-19. “For
TB Alliance Board of Directors Appoints Two New Members
NEW YORK (Sept 19, 2022)—TB Alliance welcomes Kim Schwartz and Rasha Hibri to its Board of Directors. Their expertise will
Drug-Resistant TB Trial Results Published in New England Journal of Medicine
Results of ZeNix Trial Show Effectiveness of BPaL Regimen for Highly Drug-Resistant TB Can Be Maintained with Reduced Dosing of